| Title: | Leukemia Relapse Trial |
| Purpose: | The purpose of this study is to determine patient outcomes following high-dose combination chemotherapy treatment and to compare higher versus standard dose vincristine chemotherapy. |
| Study Number: | 200749041608 |
| Number of Patients: | 10 |
| Elgibility: |
You may be eligible to participate if you have a diagnosis of acute lymphoblastic leukemia relapse or an initial diagnosis of intermediate risk acute lymphoblastic leukemia
|
| Treatment: | You will go on one of two different treatment plans. The plan you are assigned to is decided by randomization (chance). The only difference between treatments of the two plans is that participants will receive a different dose of vincristine during some stages of therapy. Some participants will be randomized to receive the standard dose of vincristine during treatment; others will get a higher dose of vincristine. The treatment plan involves cancer-fighting medicine called chemotherapy and may include radiation therapy. Treatment on this clinical trial will take about 27 months (a little over two years). It is divided into seven stages: Induction 1; Induction 2; Induction 3; Intensification 1; Re-induction; Intensification 2 and Maintenance. After the Induction 3 phase of treatment, participants who have a matched family member who is a suitable donor for bone marrow transplant will be recommended to have a bone marrow transplant rather than receive the rest of the chemotherapy treatment. |
| Principal Investigator: |
Ricarchito Manera, M.D. |
| Enrollment Phone: | (708) 216-2026 |
| |
| |
| |
|
